Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.46 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.46 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.44 |
| ▸ | GAPDH | P04406 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20485764 | 1.00 | HIF1A (0.48) | HIF1AHSPA5HSPA8DOT1LGAPDH | |
| SCHEMBL20434908 | 1.00 | HIF1A (0.48) | HIF1AHSPA5HSPA8DOT1LGAPDH | |
| SCHEMBL16727957 | 1.00 | HIF1A (0.48) | HIF1AHSPA5HSPA8DOT1LGAPDH | |
| SCHEMBL16715133 | 1.00 | HIF1A (0.48) | HIF1AHSPA5HSPA8DOT1LGAPDH | |
| SCHEMBL29325495 | 1.00 | HIF1A (0.48) | HIF1AHSPA5HSPA8DOT1LGAPDH | |
| SCHEMBL25495855 | 1.00 | HIF1A (0.48) | HIF1AHSPA5HSPA8DOT1LGAPDH | |
| SCHEMBL29323405 | 1.00 | HIF1A (0.48) | HIF1AHSPA5HSPA8DOT1LGAPDH | |
| SCHEMBL17130296 | 1.00 | HIF1A (0.48) | HIF1AHSPA5HSPA8DOT1LGAPDH | |
| SCHEMBL15548668 | 0.83 | ADK (0.44) | HIF1ADOT1LGAPDHADORA3DPP4 | |
| SCHEMBL866579 | 0.82 | ATG7 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | claimed |
| EP-3868384-B1 | CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2026-02-25 | — | — | EP | disclosed |
| US-20250205270-A1 | ANTIBODY-DRUG CONJUGATE PRECURSORS COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-26 | — | — | US | disclosed |
| US-12171777-B2 | Methods of making a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-12-24 | — | — | US | disclosed |
| EP-3334745-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-20150274767-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| WO-2015148746-A1 | 4'-SUBSTITUTED NUCLEOSIDE-DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| US-20150274767-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150141490-A1 | PYRAZOLOTRIAZOLYL NUCLEOSIDE ANALOGUES AND OLIGONUCLEOTIDES COMPRISING THEM | BIO-LAB LTD. (IL) | 2015-05-21 | — | — | US | disclosed |
| EP-2854813-A1 | PYRAZOLOTRIAZOLYL NUCLEOSIDE ANALOGUES AND OLIGONUCLEOTIDES COMPRISING THEM | Bio-lab Ltd. (IL) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013179289-A1 | PYRAZOLOTRIAZOLYL NUCLEOSIDE ANALOGUES AND OLIGONUCLEOTIDES COMPRISING THEM | BIO-LAB LTD. (IL) | 2013-12-05 | — | — | WO | disclosed |
| US-8344132-B2 | Methods for the preparation of 9-deazapurine derivatives | BioCryst Pharmaceticals, Inc. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344132-B2 | Methods for the preparation of 9-deazapurine derivatives | BioCryst Pharmaceticals, Inc. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | HIF1A 3945/4885HSPA5 1922/4885HSPA8 2045/4885 |
| US-12171777-B2 | Methods of making a cyclic dinucleotide | STING1, CGAS, MAVS | HIF1A 3227/4885HSPA5 1925/4885HSPA8 2068/4885 |
| US-20150141490-A1 | PYRAZOLOTRIAZOLYL NUCLEOSIDE ANALOGUES AND OLIGONUCLEOTIDES COMPRISING THEM | NT5C2, TK2, DUT | HIF1A 4335/4885HSPA5 1792/4885HSPA8 2843/4885 |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | DPYD, TYMP, UNG | HIF1A 1572/4885HSPA5 2687/4885HSPA8 3362/4885 |
| US-20250205270-A1 | ANTIBODY-DRUG CONJUGATE PRECURSORS COMPRISING A CYCLIC DINUCLEOTIDE | STING1, CGAS, TLR9 | HIF1A 3864/4885HSPA5 2401/4885HSPA8 2315/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | HIF1A 3945/4885HSPA5 1922/4885HSPA8 2045/4885 |
| US-20150274767-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DUT, HPRT1, RNGTT | HIF1A 1842/4885HSPA5 4096/4885HSPA8 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.